




9–12 December 2025
Adelaide Convention Centre
South Australia

www.ascept-hypertensionau.com.au

Tuesday 9 December 2025

| | | | | |
|---------------|--|---|---|---|
| 08:30 – 18:00 | Registration desk open | | | Foyer E |
| Room | E1 | E2 | E3 | Hall C Lower Section |
| 09:00 – 11:00 | WORKSHOP 1 Binding affinity prediction with deep learning: practical workshop using PSICHIC model | WORKSHOP 2 ANZ Prescribing Skills Assessment 100 Question Challenge | | WORKSHOP 3 2025 Australian Guideline for the Diagnosis and Management of Hypertension |
| Chair | Emma van der Westhuizen, St Vincent's Institute | A/Prof Kellie Charles, The University of Sydney and Dr Paul Chin, University of Otago | | Prof Gerry Jennings AO, Heart Foundation |
| | Facilitators: Dr Anh Thi Ngoc Nguyen, Monash University Huan Yee Koh, Monash University | Introduction to generative AI MCQ agents for drafting ANZ PSA exam questions A/Prof Matt Doogue, University of Otago & Health New Zealand | | Facilitators: Prof Markus Schlaich, Hypertension Centre, Royal Perth Hospital, University of Western Australia Dr Dannii Dougherty, Heart Foundation Prof Garry Jennings AO, Heart Foundation Prof Ross Tsuyuki, University of Alberta |
| 11:00-11:30 | Comfort break | | | |
| 11:30 – 13:30 | WORKSHOP 4 Assessing student understanding and application of the core concepts of pharmacology | WORKSHOP 5 From pipettes to policy: a world of career choices (combined ASCEPT& HA ECR committee) | WORKSHOP 6 What's the "T" | Hypertension Taskforce Summit (11.15-16.45) |
| Chair | Prof Paul White, Monash University | Hericka Figueiredo Galvao, La Trobe University, Alemayehu Jufar, The Florey Institute of Neuroscience and Mental Health, Aisling McEvoy, Monash University and Mariah Stavrou, UNSW Sydney | Dr Felicity Grzemeski, Novotech-cro and Tarah Hogen, SLR Consulting Australia Pty Ltd | Markus Schlaich, Royal Perth Hospital - University of Western Australia |
| | Facilitators: Prof Paul White, Monash University Dr Suong Ngo, The University of Adelaide Dr Tori Llewelyn, Flinders University A/Prof Tina Hinton, The University of Sydney A/Prof Betty Exintaris, Monash University A/Prof Lynette Fernandes, University of Western Australia Dr Marina Junqueira Santiago, Macquarie University Dr Anna-Marie Babey, University of New England Dr Gregg Maynard, Charles Sturt University Dr Nilushi Karunaratne, Monash University | Panel: Dr Wubshet Tesfaye, University of Queensland Dr Aili Langford, The University of Sydney Dr George Tan, Monash University Dr Quynh Dinh, RMIT University Dr Rikeish R Muralitharan, Monash University, Victorian Heart Institute Dr Audrey Adj, Victor Chang Cardiac Research Institute and St Vincent's Centre for Applied Medical Research | The interdisciplinary life of an academic toxicologist A/Prof Paul Wright, RMIT University The interdisciplinary life of a consultant toxicologist and health risk assessor Tarah Hagen, SLR Consulting Australia Pty Ltd Careers in nonclinical toxicology in a Contract Research Organisation Lynne Clapham, Agilix Biolabs Role of a Toxicologist in Clinical Trial Initiation and Progression Dr Sharleen Menezes, Novotech Role of Clinical Toxicologist in the medical setting Prof Nick Buckley, The University of Sydney Toxicology roles in Government Effi Liden, Australian Pesticides & Veterinary Medicines Authority The role of the toxicologist in the Therapeutic Goods Administration (TGA) and regulatory science Adj A/Prof Brian Priestly, Monash University | |
| 13:30-14:00 | Education Forum AGM | Student Forum AGM | | |
| 13:30-14:00 | Comfort break | | | |
| 14:00 – 16:00 | WORKSHOP 7 Evaluation of Individual Patient Applications (IPAs) for unfunded Medications | WORKSHOP 8 Crash-course on quantification of allosteric and biased signalling at G protein-coupled receptors | WORKSHOP 9 Visibility in STEM and Medical Practice/Research/Higher Education: Empowering Diverse Voices | |
| Chair | Nicholas Farinola, Central Adelaide Local Health Network and Tilenka Thynne, Flinders Medical Centre | Dr Celine Valant, Monash University | Audrey Adj, Victor Chang Cardiac Research Institute and St Vincent's Centre for Applied Medical Research and Brendan Wilkins, UNSW Sydney | |
| | Facilitators: A/Prof Matt Doogue, University of Otago & Health New Zealand Dr Sally Fotheringham, Royal Prince Alfred Hospital Dr David Liew, Austin Health Dr Angela Molga, Central Adelaide Local Health Network | Facilitators: Dr Shane Hellyer, Monash Institute of Pharmaceutical Sciences Dr Celine Valant, Monash University Dr Vi Pham, Monash Institute of Pharmaceutical Science Jasmin Li, Monash University Dr Arisbel Batista Gondin, Monash University | Presenters: A/Prof Courtney Ryder, Flinders University Conjoint A/Prof Darren Roberts, Sydney Local Health District; Sydney Children's Hospital Network | |

| | | | | |
|----------------------|--|---|--|---|
| 07:00 – 08:00 | Morning run/walk (free activity) Meeting point: Adelaide Rowing Club | | | |
| 07:30 – 18:00 | Registration desk open | | | Foyer E |
| 08:00 – 08:50 | 200. ASCEPT Keynote presentation: BPS lecture I Role of Endothelial Receptors in the Hypertension Induced by VEGFR-2 Inhibitors Prof Jeanette Woolard, University of Nottingham | | | Hall C Lower Section |
| Chair | Dr Bridin Murnion, St Vincent's Hospital; UNSW Sydney | | | |
| CONCURRENT SESSION 1 | | | | |
| Room | E1 | E2 | E3 | Hall C Lower Section |
| 09:00 – 10:30 | Oral presentations 1: Education & Gillian Shenfield Early Educator Award | Oral presentations 2: Pharmacoepidemiology | Oral presentations 3: Clinical pharmacology Sponsored by  | Oral presentations 4: Cognition and brain injury |
| Chair: | Assist/Prof Iris Lim, Bond University and Dr George Tan, Monash University Kellie Charles (GS award) | Dr Emily Reeve, Monash University and Harry Le, The University of Sydney | Kerry Watts, Advanced Therapeutics NSW Ministry of Health and Dr Chris Cameron, Wellington Hospital | Dr Adriana Knezic, Monash University and Prof Gavin Lambert, Swinburne University of Technology |
| 09:00-09:15 | 201. Rethinking Assessment: OSPEs Provide Authentic Alternatives in the Generative AI Era Dr Nilushi Karunaratne, Monash University | 207. Prescription sequence symmetry analysis of glucagon-like peptide-1 receptor agonist and neuropsychiatric conditions Dr George Tan, Monash University | 213. Pharmacokinetics, and efficacy/safety, of thioguanine suppositories in patients with refractory proctitis Prof Murray Barclay, Christchurch Hospital | 219. Safety and efficacy of RDN post-stroke: results from the Global SYMPLICITY Registry Gianni Sesa-ashton, Baker Heart and Diabetes Institute |
| 09:15-09:30 | 202. Are interactive oral interview assessments only useful as a secure AI assessment? A/Prof Kellie Charles, The University of Sydney | 208. Drug Burden Index–guided stewardship intervention to deprescribe in Older Acute Inpatients Dr Kenji Fujita, Kolling Institute | 214. Is one-dose-for-all suitable for low dose colchicine in patients with gout? A/Prof Daniel Wright, The University of Sydney | 220. Pre-existing Heart Failure Exacerbates Neuroinflammation After Cardiopulmonary Bypass Dr Lindsea Booth, Florey Institute |
| 09:30-09:45 | 203. How does generative AI impact student motivation and academic self-efficacy? A/Prof Tina Hinton, The University of Sydney | 209. Clusters of psychotropic and health service use in people with dementia Edward Chun Yin Lau, The University of Sydney | 215. Is it time to replace the ‘prescription’ with the medication management plan? A/Prof Matt Doogue, University of Otago & Health New Zealand | 221. Cardiovascular mechanobiomarkers relate to poorer cognition in older Australians. The Mind-Your-Heart Study Dr Louise Goodall, Garvan Institute |
| 09:45-10:00 | 204. Sustainable organ bath pharmacology experiments for continued experiential learning in science Dr Brent McParland, The University of Sydney | 210. Mapping multimorbidity clusters in older Australians using linked administrative health data Dr Edwin Tan, The University of Sydney | 216. Therapeutic benefits of megadose sodium ascorbate for blood pressure management in sepsis Maya Bishop, The University of Melbourne | 222. Associations of blood pressure parameters with cognitive decline and dementia: umbrella review Dr Sultana Shajahan, The George Institute for Global Health |
| 10:00-10:15 | 205. Health professional co-teaching teams enhance clinical pharmacology learning and teaching in optometry Dr Tori Llewelyn, Flinders University | 211. Age-stratified trends in Australian prescribing of controlled ovarian hyperstimulation medications between 2016-2024 Toni Michael, The University of Sydney | 217. Predictors of non-cardiovascular readmissions in multimorbid adults with heart failure Dr Joshua Inglis, Flinders Medical Centre | 223. Association between Arterial Stiffness and Cognitive Decline in an Older Chinese Population Dr Audrey Adjii, Victor Chang Cardiac Research Institute and St Vincent's Centre for Applied Medical Research |
| 10:15-10:30 | 206. Strategies for effective teamwork in the pharmacology practical class (Gillian Shenfield Early Educator Award) Dr Makhala Khammy, The University of Melbourne | 212. Incidence and profiles of poisonings in older people with dementia in Sweden Ilsa Wojt, The University of Sydney | 218. Co-design of medication management resources for people with dementia in the community Xenia Nastatos, The University of Sydney | 224. Seizure-induced cardiovascular dysregulation: a clinically relevant sheep model for SUDEP therapeutics development Dr Ruslan Pustovit, Florey Institute of Neuroscience and Mental Health |
| 10:30 – 11:00 | Morning tea with exhibitors | | | Foyer E |
| 10:30-11:00 | Poster presentations Cardiovascular, Innovation & Industry, Clinical pharmacology, Drug discovery, Pharmacoepidemiology, Pharmacogenomics, Comorbidities, Complications of hypertension, Mechanisms of hypertension, Risk factors | | | |
| CONCURRENT SESSION 2 | | | | |
| Room | E1 | E2 | E3 | Hall C Lower Section |
| 11:00 – 13:00 | Symposium 1: Toxicology Today and Tomorrow: Global Trends in Focus, Techniques and Regulation | Symposium 2: Genetic diversity in drugs targets | Symposium 3: Cardiorespiratory immunopharmacology: state-of-the-art models and novel drugs | Symposium 4 (HA): Advances in treatment for paediatric hypertension and obesity |
| Chair | Dr Ian Musgrave, University of Adelaide and Tayler Catherine Kent, Murdoch University | Dr Pramod Nair, Flinders University and Dr Eryn Werry, The University of Sydney | A/Prof Graham Mackay, University of Melbourne | A/Prof Jonathan Mynard, Murdoch Children’s Research Institute and Adj A/Prof Rae-Chi Huang, Edith Cowan University and Perth Children’s Hospital |
| 11:00-11:30 | 225. Climatoxicology: ACTRA warns that climate change is impacting the toxicology and risk assessment of chemical exposures A/Prof Paul Wright, RMIT University | 229. New therapeutics from neo-epitope sequences for myelofibrosis A/Prof Daniel Thomas, University of Adelaide, SAHMRI | 233. Environmental Exposures on the Cardiorespiratory system: New Models, Drug Targets and Treatment Approaches Dr Richard Kim, University of Technology Sydney | 237. Emerging therapies for treatment resistant hypertension Prof Markus Schlaich, Dobney Hypertension Centre, Royal Perth Hospital, University of Western Australia |
| 11:30-12:00 | 226. Toxicology challenges of emerging pharmaceutical modalities Dr Sharleen Menezes, Novotech | 230. Development of radiotracers for TSPO polymorphisms Grace Cumbers, The University of Sydney | 234. Advancing Strategies in Cardiopulmonary Disease: Pioneering Pathways to Therapeutic Innovation Dr Chengxue Helena Qin, Monash University | 238. New Australian Guideline for Children and Adolescents - when, why and how to manage BP in children Dr Nicholas Larkins, Perth Children’s Hospital |
| 12:00-12:30 | 227. Thought for food: assessing agricultural risks from PFAS in the current regulatory environment Tarah Hagen, SLR Consulting Australia Pty Ltd | 231. Patients carrying epilepsy-causing variants in GABAA receptors require treatments based on a precision medicine approach Prof Mary Chebib, The University of Sydney | 235. Thinking Outside the Box: Immune-Modifying Methods to Reduce Lung Infections on the Cardiovascular System Dr Madison Coward-Smith, University of Technology Sydney | 239. DASH diet resource to support lifestyle intervention for paediatric hypertension Arielle Hyland, Perth Children’s Hospital |
| 12:30-13:00 | 228. Non-animal models: Current status for toxicology and specific challenges including virtual control groups, in silico modelling, AI predictive tools, organ on a chip/organoids Dr Slade Matthews, The University of Sydney and Lynne Clapham, Agilix Biolabs | 232. Novel GRM1 mutations in juvenile ataxia Dr Shane Hellyer, Monash Institute of Pharmaceutical Sciences | 236. Endogenous TGF-β immune suppression in chronic inflammatory lung disease Dr Belinda Thomas, Monash University | 240. Emerging treatments for obesity in children, and impact on blood pressure Dr Danielle Longmore, Royal Children’s Hospital |

| | | | | | |
|----------------------|--|--|--|--|-----------------|
| 13:00 – 14:00 | Lunch with exhibitors | | | <div>Sponsored by</div> <div></div> | Foyer E |
| 13:00 – 14:00 | Poster presentations Cardiovascular, Innovation & Industry, Clinical pharmacology, Drug discovery, Pharmacoepidemiology, Pharmacogenomics, Comorbidities, Complications of hypertension, Mechanisms of hypertension, Risk factors | | | | |
| 13:15 -14:00 | Hypertension Australia Board Meeting | | | | Skyway Room 1&2 |
| 13:00-14:00 | LUNCH WORKSHOP: Leveraging Novel Methodologies to Address Key Challenges in Drug Discovery and Development Dr Kenneth Brouwer, BioIVT | | | <div>Presented by</div> <div></div> | E1 |
| CONCURRENT SESSION 3 | | | | | |
| Room | E1 | E2 | E3 | Hall C Lower Section | |
| 14:00 – 15:30 | Oral presentations 5: Toxicology / Innovation and industry | Oral presentations 6: Drug discovery / Pharmacogenomics | Oral presentations 7: Cardiovascular / Respiratory and inflammation | Oral presentations 8: New therapies and management of hypertension | |
| Chair | Dr Susan Britza, The University of Adelaide and Dr Brendan Wilkins, UNSW Sydney | Toni Michael, The University of Sydney and Prof Kevin Pflieger, The University of Western Australia | Dr Paris Papagianis, Monash University and David Wong Zhang, La Trobe University | Dr Niamh Chapman, The University of Sydney and Prof Mark Nelson, University of Tasmania | |
| 14:00-14:15 | 241. Active Learning with Thompson Sampling for hERG Risk Modelling in Drug Development Dr Slade Matthews, The University of Sydney | 247. Bi-specific diabodies targeting β-amyloid to microglial phagocytic proteins for treating neurodegenerative diseases Dr Emma Van Der Westhuizen, St Vincent's Institute of Medical Research | 253. Microbial Metabolite Receptor FFA2 Improves Post-Ischaemic Reperfusion Dr Kristen Bubb, Monash University | 259. The effect of aprocitentan in patients with very high baseline blood pressure Prof Markus Schlaich, Royal Perth Hospital - University of Western Australia | |
| 14:15-14:30 | 242. Novel informatics approaches for the regulatory management of UVCB substances Hannah Gerstmyer, The University of Sydney | 248. Applying Artificial Intelligence to develop high-affinity antagonists of the relaxin receptor, RXFP1 Prof Ross Bathgate, Florey Institute of Neuroscience and Mental Health | 254. Bromodomain extra-terminal inhibitors prevent inflammation-induced stromal cell signalling & cardiac dysfunction A/Prof Simon Foster, Cardiac Drug Discovery Lab, QIMR Berghofer | 260. Chronic hypertension in young women – are we adequately preparing for pregnancy? Dr Madeleine Cosgrave, Eastern Health Clinical School, Monash University | |
| 14:30-14:45 | 243. Isolated compounds from ginseng and green tea increase oxidative stress in spermatozoa Dr Tayler Catherine Kent, Murdoch University | 249. Development of P2Y2 receptor antagonists with improved physicochemical properties for drug discovery Dr Natasha Dale, The University of Nottingham | 255. Marginal Zone B cells: potential drivers of inflammation associated with hypertension Dr Hericka Bruna Figueiredo Galvao, La Trobe University | 261. Australia lacks a high-quality national database system on blood pressure Dr Alexandra Gallagher, The University of Sydney | |
| 14:45-15:00 | 244. Assessing the impact of Phenazopyridine on the efficacy of BCG-immunotherapy Georgia Bourlotos, Flinders University | 250. Structure-Guided Design of Allosteric Modulators at the Delta Opioid Receptor Dr Arisbel Batista Gondin, Monash University | 256. Retinal capillary rarefaction is associated with systemic immune-inflammatory index in hypertensive patients Dr Louise Woodhams, Dobney Hypertension Centre | 262. Improved cardiovascular disease risk management via pathology services: a randomised clinical trial Prof James Sharman, Menzies Institute for Medical Research | |
| 15:00-15:15 | 245. Towards Safer Medication Practices: A Retrospective Analysis of Adverse Drug Reactions Jing Xin Goh, The University of Sydney | 251. Co-trimoxazole-induced SCAR is globally defined by HLA-B alleles with shared peptide-binding specificities A/Prof Andrew Gibson, Murdoch University | 257. Low-dose Australian air pollution promotes neutrophilic, steroid-insensitive, experimental asthma Hudson Taylor-Blair, The University of Technology Sydney | 263. What attributes influence antihypertensive prescribing to older adults? A discrete choice experiment Dr Edel O'hagan, Westmead Applied Research Centre, The University of Sydney | |
| 15:15-15:30 | 246. A novel GPCR heteromer demonstrates unique pharmacology revealed with live cell biosensors Henry Purbrick, The University of Western Australia | 252. Implementation of a pharmacogenomic testing service in residential aged care: Preliminary findings Eman Wehbe The University of Sydney | 258. Targeting C-C motif chemokine receptor 6 with PF-07054894 in COPD William Dewar, University of Technology Sydney | 264. Impact of packaging aids on medication errors: a systematic scoping review Ngoc Tran, The University of Sydney | |
| 15:30 – 16:00 | Afternoon tea with exhibitors | | | | Foyer E |
| 15:30 – 16:00 | Poster presentations Cardiovascular, Innovation & Industry, Clinical pharmacology, Drug discovery, Pharmacoepidemiology, Pharmacogenomics, Comorbidities, Complications of hypertension, Mechanisms of hypertension, Risk factors | | | | |
| 15:30 – 16:00 | Toxicology AGM | Pharmacogenomics AGM | Respiratory & Inflammation AGM | Neuropharmacology AGM | |

Bridging the Gap: Assessing Aldosterone Synthase Inhibition in Hypertension Management

Join the workshop Thursday, 11th December, 1:00 PM – 2:00 PM Hall E1

<https://www.astrazeneca.com.au/>
AU – 23986
Date: NOV 2026







Comprehensive Biospecimen Solutions

BIOIVT.COM

ASCEPT – Hypertension Australia Joint Scientific Meeting 2025

Page 4

| Room | E1 | E2 | E3 | Hall C Lower Section |
|---------------|---|----|---|---|
| 16:00 – 18:00 | Bellberry New Investigator Award Sponsored by  | | | HA student oral finalists 16:00-17:15 |
| Chair | Prof Andrew Rowland, Flinders University Dr Mouna Sawan, The University of Sydney | | | Prof Francine Marques, Monash University and Dr Dean Picone, The University of Sydney |
| | 265. Psilocybin-assisted psychotherapy: A trans-diagnostic therapy? Dr Jonathan Brett, UNSW/St. Vincent's Hospital 266. Characterising a rat model of polycystic kidney disease to identify therapeutic targets Dr Quynh Dinh, RMIT University 267. Understanding sex-based cardiometabolic responses to contemporary diabetes therapies' Dr Abhipree Sharma, Monash University 268. Novel in vivo and ex vivo applications utilising transgenic TGFβ overexpressing mice Dr Julia Chitty, Monash University | | | 269. Reimagining Hypertension Care: Feasibility and Acceptability of Remote Wearable Blood Pressure Monitoring Heshmiha Christy, UNSW Sydney 270. Hypertensive response to exercise, fitness, left ventricular hypertrophy and cardiovascular outcomes Catalina Silva Ruiz, The University of Tasmania 271. Interleukin-18 signals via a non-canonical short IL-18 pathway during deoxycorticosterone/salt-induced hypertension Buddhila Wickramasinghe, La Trobe University 272. High-fibre diet intervention post-stroke is protective in male but not female mice Charlotte Barker, Monash University 273. Exploring the role of steroid profiling in understanding the pathophysiology of hypertension Dr Sonali Shah, Hudson Institute of Medical Research |
| 17:15-17:45 | 274. HA Lecture: RD Wright I Body fluids and blood pressure: lost in translation A/Prof Jens Titze, DukeNUS Medical School | | Sponsored by  | Hall C Lower Section |
| 17:45-18:15 | 275. HA Lecture: Paul Korner Awardee Lecture I Hormones and Hypertension; Medicine and Music Prof Michael Stowasser, Frazer Institute, The University of Queensland, Princess Alexandra Hospital | | | |
| Chair | Prof Markus Schlaich, Royal Perth Hospital - University of Western Australia | | | |
| 18:30-20:00 | ASCEPT&HA Presidents' Reception | | | Gilbert Suite |
| 19:00-22:00 | Student Dinner | | | Lady Burra Brewhouse |



Supporting better health outcomes

Therapeutic Guidelines recognised as a leading source of accurate, independent, and practical treatment advice for a wide range of clinical conditions.

More than 2,500 topics covering disorders encountered in clinical practice, integrated into a single product for your computer or mobile.

tg.org.au



| | | | | |
|----------------------|--|--|--|---|
| 07:30 – 17:00 | Registration desk open | | | Foyer E |
| 07:00-08:00 | HA Round table | | | Skyway room 1&2 |
| 08:00-08:30 | 300. HA Lecture: Austin Doyle I Functional testing in autoinflammatory diseases Prof Seth Masters, Centre for Innate Immunity and Infectious Disease, Hudson Institute of Medical Research | | | Hall C Lower Section |
| 08:30-09:00 | 301. HA Lecture: Colin I Johnston Lecturer I Rewriting blood pressure control through the gut microbiome: A translational odyssey Prof Francine Marques, Monash University | Sponsored by  | | |
| Chair | Prof Markus Schlaich, Royal Perth Hospital - University of Western Australia | | | |
| CONCURRENT SESSION 4 | | | | |
| Room | E1 | E2 | E3 | Hall C Lower Section |
| 09:00 – 10:30 | Oral presentations 9: Clinical pharmacology & Tony Smith QUM Prize | Oral presentations 10: Pharmacoepidemiology & Clinical pharmacology trainee | Oral presentations 11: Urogenital and gastrointestinal / Neuropharmacology | Oral presentations 12: Complications and comorbidities of hypertension |
| Chair | Dr Josh Inglis, Flinders Medical Centre and Dr Bridin Murnion, St Vincent's Hospital; UNSW Sydney | Darshna Goordeen, Monash University and Dr George Tan, Monash University | Assist/Prof Iris Lim, Bond University and Dr Celine Valant, Monash Institute of Pharmaceutical Sciences | Dr Hericka Figueiredo Galvao, La Trobe University and A/Prof Antony Vinh, La Trobe University |
| 09:00-09:15 | 302. Adverse drug withdrawal event identification and adjudication Dr Emily Reeve, Monash University | 308. Residential aged care quality use of medicines indicators: a Delphi study Dr Daria Gutteridge, The University of South Australia | 314. Reversible inhibition of bladder mucosa contractile activity by dimethylsulfoxide (DMSO) Prof Russ Chess-Williams, Centre for Urology Research, Bond University | 320. Clinical decision-making in primary aldosteronism screening, diagnosis and management: A qualitative study Dr Sandra Hakim, Monash University |
| 09:15-09:30 | 303. Beyond blood: feasibility of saliva-based assays for antiviral therapeutic drug monitoring Cassandra Lai, The University of Sydney | 309. Psychotropic use in community-dwelling people with dementia: a systematic review and meta-analysis Edward Chun Yin Lau, Sydney Pharmacy School, The University of Sydney | 315. Female mice exhibit reduced hallmarks of MASH in the GAN DIO model Isabella Simon, Monash University | 321. Heart failure exacerbates renal hypoxia and acute kidney injury after cardiopulmonary bypass Prof Clive May, Florey Institute of Neuroscience and Mental Health |
| 09:30-09:45 | 304. Medication data collection in Frailty Intervention Through Specific Therapies (FITTEST) trial participants Temitope Esther Afolabi, The University of Sydney | 310. Adverse Outcomes Associated with Risperidone in Dementia: An Individual Participant Data Meta-Analysis Harry Le, The University of Sydney | 316. Unravelling the mechanisms underlying BCG induced lower urinary tract side effects Meera Elmasri, Flinders University | 322. Sex differences in response to podocyte depletion in aged mice Dr Sarah Walton, Monash University |
| 09:45-10:00 | 305. Navigating Complexity: Developing a Regulatory Pathway for Advanced Therapeutics in Australia (Tony Smith QUM Prize finalist) Kerry Watts, NSW Ministry of Health | 311. Impact of medication management interventions on healthcare utilisation in dementia: Systematic review Jiefei Yu, The University of Sydney | 317. Targeting endosomal metabotropic glutamate receptor 5 signalling for the treatment of pain Dr Shane Hellyer, Monash Institute of Pharmaceutical Sciences | 323. Linking Renal Medullary Hypoxia to Mitochondrial Dysfunction in Septic Acute Kidney Injury Dr Connie Ow, Florey Institute of Neuroscience and Mental Health |
| 10:00-10:15 | 306. What support Healthcare Professionals need to deprescribe opioids at transitions of care (Tony Smith QUM Prize finalist) Jeffery Wang, The University of Sydney | 312. A qualitative evidence synthesis on the unintended consequences of prescription opioid policies Patrick Lu, The University of Sydney | 318. Untangling Polypharmacy Molecular Signature Through Network Pharmacology Approaches: Study on Hippocampal Proteomics Kevin Winardi, The University of Sydney & Kolling Institute | 324. Beyond diet and obesity: establishing a sympathetic nervous system-driven model of MAFLD Dr Lakshini Herat, Dobney Hypertension Centre, The University of Western Australia |
| 10:15-10:30 | 307. Patient Decision-Aids for Pain Medication Management: A Scoping Review (Tony Smith QUM Prize finalist) Dr Aili Langford, The University of Sydney | 313. Systematic review evaluating efficacy and safety of colchicine in coronary artery disease Dr Deisi Christopher, Flinders Medical Centre | 319. Kv1.3 blockade improves cognitive performance in APP/PS1 mice Dr Ryan Keenan, Monash University | 325. Megadose sodium ascorbate attenuates splanchnic sympathetic nerve activity in Gram-negative rodent sepsis Dr Rachel Peiris, The Florey Institute of Neuroscience and Mental Health |
| 10:30– 11:00 | Morning tea with exhibitors | | | Foyer E |
| 10:30– 11:00 | Poster presentations Toxicology, Urogenital and gastrointestinal, Education, Neuropharmacology, Respiratory and inflammation, Clinical trials and blood pressure measurement, New therapies, Hypertension - Other, Public health and epidemiology | | | |
| CONCURRENT SESSION 5 | | | | |
| Room | E1 | E2 | E3 | Hall C Lower Section |
| 11:00 – 13:00 | Symposium 5: Consumer and community involvement in hypertension and pharmacology research | Symposium 6: From Trial-and-Error to Precision: Pharmacogenomic-Guided Medication Use in Mental Health Care | Symposium 7: Transforming Lung Cancer: from Discovery to Delivery | Symposium 8 (HA): A Pinch of Salt: New Insights into Blood Pressure Regulation |
| Chair | Dr Lisa Kouladjian O’Donnell and Dr Mouna Sawan, The University of Sydney | A/Prof Sophie Stocker, The University of Sydney and Dr Sam Mustafa, myDNA Life Australia | Dr Richard Kim, University of Technology Sydney and Mariah Stavrou, UNSW Sydney | A/Prof Anthony Vinh, La Trobe University and Dr Katrina Mirabito Colafella, Monash University |
| 11:00-11:30 | 326. Meaningful engagement to develop culturally relevant health interventions with Aboriginal and Torres Strait Islander people Dr Andrew Goodman, The Australian e-Health Research Centre, CSIRO | 329. Translating pharmacogenomics and precision dosing in major depressive disorder: the ALIGNED study A/Prof Kathy Wu, St Vincent’s Hospital | 333. Development of a biologically-selective treatment for lung adenocarcinoma A/Prof Nicola Smith, UNSW Sydney | 337. Nitrogen metabolism in salt-sensitive hypertension A/Prof Jens Titze, DukeNUS Medical School |
| 11:30-12:00 | 327. Creating Opportunities for Consumer Involvement: Reflections of a Discovery Scientist and Research Centre Director Prof Grant Drummond and Dr Vivian Tran, La Trobe University | 330. The PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind RCT of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care Dr Sibel Saya, The University of Melbourne | 334. A novel model of air pollution-induced lung cancer Dr Chantal Donovan, University of Technology Sydney | 338. Implementing potassium-enriched salt substitutes in Australia and globally to reduce blood pressure on a population level Prof Alta Schutte, UNSW Sydney and The George Institute for Global Health |
| 12:00-12:30 | 328. Ingredients for successful partnerships between researchers and consumers John Stevens and Dr Niamh Chapman, The University of Sydney | 331. The science of delivering pharmacogenomic test results to guide prescribing in Australia Prof Luke Hesson, Douglass Hanly Moir Pathology | 335. TRACKER Biobank: empowering lung cancer breakthroughs Dr Senthuran Shivakumar, University of Melbourne and Austin Health | 339. Salty guts: A high salt diet promotes atherosclerosis through a gut-bone marrow axis Prof Andrew Murphy, Baker Heart and Diabetes Institute |
| 12:30-13:00 | Panel discussion and Q&A | 332. The value proposition: Is pharmacogenomic-guided prescribing of medicines to treat mental health conditions economically sound? Prof Christine Lu, Royal North Shore Hospital, The University of Sdney | 336. Sequencing approaches for improving diagnosis – insights from industry Dr Baoming Wang, University of Technology Sydney | 340. Sodium & Sensibility: The Gendered Tale of Salt Regulation Dr Zoe McArdle, Monash University |

| | | | | |
|----------------------|---|--------------------------|--|--|
| 13:00 – 14:00 | Lunch with exhibitors | | | Foyer E |
| 13:00 – 14:00 | Poster presentations Toxicology, Urogenital and gastrointestinal, Education, Neuropharmacology, Respiratory and inflammation, Clinical trials and blood pressure measurement, New therapies, Hypertension - Other, Public health and epidemiology | | | |
| 13:00-14:00 | LUNCH WORKSHOP: Bridging the Gap: Innovations and Unmet Needs in Hypertension Care Facilitators: Prof Markus Schlaich, Royal Perth Hospital - University of Western Australia Prof Alta Schutte, UNSW Sydney Prof Michael Stowasser, University of Queensland Frazer Institute, Greenslopes and Princess Alexandra Hospitals | | LUNCH WORKSHOP: Bellberry–ASCEPT Partnership on New Approach Methodologies (NAMs) Facilitators: Prof Carl Kirkpatrick, Centre for Medicine use and safety, Monash University Prof Andrew McLachlan AM, Sydney Pharmacy School Leanne Weekes, Bellberry Kylie Sproston, Bellberry | |
| | Delivered by  | | Delivered by   | |
| Room | E1 | | E2 | |
| CONCURRENT SESSION 6 | | | | |
| Room | E1 | E2 | E3 | Hall C Lower Section |
| 14:00 – 15:30 | ASCEPT Garth McQueen Oral Prize Session | | | HA ECR oral finalists 14:00-15:00 |
| Chair | Dr Luke Grundy, Flinders University and Dr Chantal Donovan, University of Technology Sydney | | | Dr Isabella Tan, The George Institute for Global Health and Prof Ross Tsuyuki, University of Alberta |
| 14:00-14:15 | 341. Therapeutic Potential of Human Amnion Epithelial Cells for Improving Post-Stroke Cognitive Outcomes David Wong Zhang, La Trobe University | | | 347. Effects of prebiotic HAMSAB supplementation on 24-hour ambulatory blood pressure indices Dr Rikeish R Muralitharan, Monash University, Victorian Heart Institute |
| 14:15-14:30 | 342. FPR2 agonist attenuates pulmonary arterial hypertension and right ventricular dysfunction in mice Ting Fu, Monash Institute of Pharmaceutical Sciences | | | 348. IRAP Inhibition as a Novel Anti-Fibrotic Strategy for Post-MI Heart Failure Dr Yan Wang, Monash University |
| 14:30-14:45 | 343. IRAP – A novel target in the treatment of Pulmonary Arterial Hypertension Supitchaya (Leena) Watakul, Monash University | | | 349. Low dietary fibre: a sex-dependent regulator of inflammation and blood pressure Dr Joanne O'Donnell, Monash University |
| 14:45-15:00 | 345. Protection in IRAP deficient mice differs between photothrombotic and MCAO induced stroke Rianna Tadd-Lennox, Monash University | | | 350. Ad hoc use of home blood pressure monitoring undermines clinical utility Dr Annika Wilson, The University of Tasmania |
| 15:00-15:15 | 346. Modeling acute silica-induced inflammation using precision-cut lung slices Varuni Premaratne, Monash University | | | |
| 15:00- 15:30 | 351. BIHS Lecture I Hypertensive pregnancy: a truly multi-organ disorder...can the postpartum period offers a window to modulate lifetime risks of end organ damage? Dr Jamie Kitt, Oxford & Thames Valley | | | Hall C Lower Section |
| Chair | Dr Isabella Tan, The George Institute for Global Health and Prof Ross Tsuyuki, University of Alberta | | | |
| 15:30 – 16:00 | Afternoon tea with exhibitors | | | Foyer E |
| 15:30 – 16:00 | Poster presentations Toxicology, Urogenital and gastrointestinal, Education, Neuropharmacology, Respiratory and inflammation, Clinical trials and blood pressure measurement, New therapies, Hypertension - Other, Public health and epidemiology | | | |
| 15:30-15:55 | Drug Disposition & Response AGM | Pharmacoepidemiology AGM | Cardiovascular AGM | Innovation & Industry AGM |
| Room | E1 | E2 | E3 | Hall C Lower Section |
| CONCURRENT SESSION 7 | | | | |
| 16:00 – 17:00 | 352. Keynote presentation: ASCEPT Rand medal I From Organ Baths to Omics: Unravelling Endothelial, Oxidative and Immune Mechanisms in Cardiovascular Disease Prof Grant Drummond, La Trobe University | | | Hall C Lower Section |
| Chair | Dr Bridin Murnion, St Vincent's Hospital; UNSW Sydney | | | |
| Room | E1 | | E2 | |
| 17:00 – 18:00 | ASCEPT AGM | | HA AGM | |
| 19:00 – 23:30 | Meeting Dinner | | Sponsored by  | National Wine Centre |



Launching new futures

Adelaide University is a new institution built for a changing world.



PRV 14404/CRICOS 04249J

CELEBRATING

Winner Telstra National
Championing Health
#TelstraBestOfBusinessAward

Bb Bellberry Limited

supporting research and ethics

Australia's largest reviewer



Human Research Ethics Committees

Working across all phases of clinical and device trials, and social and behavioural studies, our teams support researchers in private, public, academic and government settings Australia-wide.

In 2024 Bellberry supported

~40%

of CTN clinical
trials in Australia

1,760+ research
organisations

7,080+ investigators
and site staff

11,250+ research
applications



We Care

HRECs Excellence
With two key objectives:
to protect the welfare
of human research
participants, and improve
the quality, efficiency and
effectiveness of research.

Learn more >



We Give

Philanthropic Activities
We support grants for
people, projects and
direct action initiatives.

Learn more >



We Lead

Research, Policy & Advocacy
We are NHMRC certified,
and AAHRPP accredited
for excellence and ethically
sound processes. The first
and only organisation to
achieve this in Australia.

Learn more >



We Innovate

Strategic Projects
Development of new
products & services to
support & improve the
excellence of scientific
& ethical review and the
delivery of research.

Learn more >



For more information about Bellberry and our services >


www.bellberry.com.au

+61 8 8361 3222

bellberry@bellberry.com.au



| | | | | |
|----------------------|---|---|--|---|
| 08:30 – 15:00 | Registration desk open Foyer | | | |
| Room | E1 | E2 | E3 | |
| 09:00-10:30 | Neville Percy Prize flash poster presentations | Robert Whelan Prize flash poster presentations | HA student poster prize presentations | |
| Chair | A/Prof Nicola Smith, UNSW Sydney and Dr Slade Matthews, The University of Sydney | Dr Luke Grundy, Flinders University and Dr Hericka Figueiredo Galvao, La Trobe University | Dr Lakshini Herat, The University of Western Australia and Dr Ruslan Pustovit, Florey Institute of Neuroscience and Mental Health | |
| 09:00-09:05 | | | 400. Deep immunophenotyping reveals associations with human blood pressure Evany Dinakis, Monash University | |
| 09:05-09:10 | | | 401. Distinct endothelial cell subtype promotes vascular inflammation and remodelling during aortic stiffening Tayla Gibson Hughes, La Trobe University | |
| 09:10-09:15 | | | 402. Microbial metabolite supplementation reduces blood pressure by improving vascular function Phoebe Cheong, Monash University | |
| 09:15-09:20 | | | 403. Arterial stiffness shows stronger association with cognitive function in females than males Genevieve Shek, UNSW Sydney | |
| 09:20-09:25 | | | 404. Human amnion epithelial cell therapy modulates brain cell heterogeneity in experimental stroke Yeshwanth Reddy Yeraddu, LaTrobe University | |
| 09:25-09:30 | | | 405. Gut microbial metabolite acetate and prevention of cardiovascular disease in high-risk women Chaoran Yang, Monash University | |
| 09:30-09:35 | | | 406. Neuroinflammation without Hypoxia, and Brain Injury Biomarkers after Cardiopulmonary Bypass in Sheep Dr Taku Furukawa, The Florey, University of Melbourne | |
| 09:35-09:40 | | | 407. Team-based hypertension care in Australia: A qualitative study among primary care providers Dr Gautam Satheesh, The University of Sydney | |
| 09:40-09:45 | Comfort break | | | |
| 9:45-10:15 | | | HA ECR poster prize presentations | |
| Chair | | | Dr Lindsea Booth, Florey Institute and Prof James Sharman, Menzies Institute for Medical Research | |
| 09:45-09:50 | | | 408. Hypertension awareness, treatment and control in Australian young adults Dr Ritu Trivedi, The University of Sydney | |
| 09:50-09:55 | | | 409. The impacts of an intracerebrally-administered hydrogel therapeutic-delivery system on the brain post-stroke Dr Adriana Knezic, Monash University | |
| 09:55-10:00 | | | 410. Impact of dialysis on cardiovascular, cerebrovascular and renovascular hemodynamics in sepsis Dr Munenori Kusunoki, Florey Institute of Neuroscience and Mental Health | |
| 10:00-10:05 | | | 411. Inadequate fibre intake increases gut-derived uremic toxins that contribute to hypertension Dr Chudan Xu, Monash University | |
| 10:05-10:10 | | | 412. VEGF inhibitor-induced hypertension is ameliorated by DMSC-EVs in male rats Dr Katrina Mirabito Colafella, Monash University | |
| 10:10-10:15 | | | | |
| 10:30 – 11:00 | Morning tea with exhibitors | | | Foyer E |
| CONCURRENT SESSION 8 | | | | |
| Room | E1 | E2 | E3 | Hall C Lower Section |
| 11:00 – 13:00 | Symposium 9: Recent applications of physiologically-based pharmacokinetics (PB-PK) in drug discovery and development | Symposium 10: The changing landscape of drug development and early phase Clinical Trials | Symposium 11: Spatial omics in drug discovery research | Symposium 12 (HA): Improving the Cardiometabolic Health of People with Intellectual Disability |
| Chair | A/Prof Dave Shackleford, Cornelia Landersdorfer and Prof Carl Kirkpatrick, Monash University | Dr Angela Molga, Central Adelaide Local Health Network | Dr Hericka Bruna Figueiredo Galvao, La Trobe University and Dr Simon Foster, QIMR Berghofer | Prof Gavin Lambert, Swinburne University of Technology and Dr Rachel Mcdonald, Medtechvic & Swinburne University of Technology |
| 11:00-11:30 | 413. Breathing Life into Physiologically Based Pharmacokinetics (PBPk): Modeling Inhaled Oxytocin for Postpartum Care Prof Carl Kirkpatrick, Monash University | 417. Unique translational clinical pharmacology challenges with novel, non-traditional drug molecules: the example of siRNA therapeutics Dr Tom Polasek, Monash University | 421. Vascular Smooth Muscle Cell Heterogeneity: New Insights into Coronary Artery Atherosclerosis Dr Maria Jelinic, La Trobe University | 425. Improving Cardiometabolic disease outcomes for people with intellectual disability Prof Julian Trollor, Disability Health, University of New South Wales |
| 11:30-12:00 | 414. Enhancing Physiologically Based Pharmacokinetic Models with Lymphatic Flow to Predict mRNA-LNP Biodistribution in Rats Dr Jessica Tait, Monash University | 418. The challenges of conducting psychedelic clinical trials Dr Jonathan Brett, UNSW Sydney and St. Vincent’s Hospital | 422. Machine learning and spatial multiomics to study drug targets and responses A/Prof Quan Nguyen, QIMR Berghofer | 426. Understanding the mechanisms of cardiac and metabolic risk in individuals with intellectual disability A/Prof Elisabeth Lambert, Swinburne University of Technology |
| 12:00-12:30 | 415. What lies beneath - PBPk modelling to support subcutaneous administration of Anakinra in preterm neonates Jia Li, Monash University | 419. Challenges of conducting trials with Complement inhibitors Dr Millie Wang, New Zealand Clinical Research | 423. Using spatial proteomics on human cardiac organoids to map cardiac cell-cell and cell-matrix interactions in fibrosis Dr Lynn Devilee. QIMR Berghofer | 427. Using co-design to improve health outcomes in disadvantaged communities Prof Rachael McDonald, The MedTechVic hub, Swinburne University of Technology |

| | | | | |
|-------------|---|--|--|---|
| 12:30-13:00 | 416. In Vitro Models Integrating Metabolism and Transport to Support Mechanistic PK Modeling in Early Drug Discovery Dr Kenneth Brouwer, PhD, RPH, BioVIT | 420. Technical aspects of modern early phase study design – what does the future of early phase clinical studies look like? Prof Sepehr Shakib, The University of Adelaide | 424. End-to-end spatial transcriptomics analysis with VR-Omics Prof Mirana Ramialison, Murdoch Children’s Research Institute | 428. Designing and implementing the Food and Lifestyle Information Program (FLIP) culinary nutrition intervention for adults with intellectual disability Dr Roberta Asher, The University of Newcastle |
| 13:00-13:45 | Lunch with exhibitors | | | Foyer E |
| 13:45-14:45 | 429. Closing Keynote address It’s what they do that counts: activity-based assays as a new approach in clinical and forensic toxicology A/Prof Christophe Stove, Ghent University | | <div>Sponsored by</div> <div></div> | Hall C Lower Section |
| Chair | Prof Nick Buckley, The University of Sydney | | | |
| 14:45-15:45 | Awards and meeting close | | | |

WORLD-CLASS PHARMACY AND PHARMACEUTICAL SCIENCE RESEARCH

The Monash Institute of Pharmaceutical Sciences (MIPS) is a dynamic, innovative and ambitious centre of research and learning, with a growing emphasis on cutting edge global projects. More than 450 MIPS scientists research drug discovery, design, delivery and use. Our therapeutic strengths lie in neuroscience and mental health, cardiovascular and metabolic health, and global health.

Find out more: monash.edu/mips



MONASH

University

MONASH

INSTITUTE OF PHARMACEUTICAL SCIENCES




Trusted information for confident decision making

- ✓ Independent and evidence-based
- ✓ Concise for point of care use
- ✓ Unique comparative insights
- ✓ Supports the Quality Use of Medicines

For more information visit amh.net.au

OMRON

BLOOD PRESSURE MONITORS



400million units sold*

Global Leaders in Home Blood Pressure Monitoring

HEM-907



Built with precision through Japanese engineering, the OMRON HEM-907 Professional Blood Pressure Monitor is designed to deliver the accuracy and reliability medical professionals demand.

Used by clinicians worldwide, OMRON's practitioner-grade monitors provide consistent, reproducible readings to support confident patient assessment and care decisions.

As a global leader in blood pressure technology, OMRON Healthcare continues to set the standard for innovation and quality in clinical measurement.

Global Home Appliance Market Comprehensive Survey 2025, Fuji Keizai Co., Ltd. (forecast for 2024)

* Global cumulative sales of home electronic blood pressure monitors (as of September 2025)